New standards in the chemotherapy of metastatic hormone-refractory prostate cancer

Teodoro Sava, Umberto Basso, Antonio Porcaro, Gian Luigi Cetto

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Hormone-refractory prostate cancer (HRPC) is a major issue in Western countries and the second leading cause of cancer death in North American men. In the prostate-specific antigen era, most HRPCs are currently diagnosed in asymptomatic patients based on biochemical failure, with increasing demand for active treatment. Until recently, chemotherapy for HRPC patients was not considered a standard of care due to the absence of clear data evidencing an overall survival benefit. In fact, few Phase III studies conducted in the 1980s and early 1990s had documented a superiority over corticosteroids alone in terms of biochemical response (declines in serum prostate-specific antigen levels) and quality of life, but not survival. Due to their impact on pain control, mitoxantrone and prednisone were long considered the best regimen for symptomatic HRPC patients. In recent years, more chemotherapeutic agents have been tested, among which the microtubule inhibitors (vinca alkaloids and taxanes) have obtained the most promising results in Phase II trials and have entered Phase III testing. Two well-designed randomized trials have changed this scenario. Both compared docetaxel (with or without estramustine) against mitoxantrone and prednisone, and demonstrated a significant advantage not only in terms of response, pain control and quality of life, but also In terms of overall survival. Which patients need to be treated, the regimen of choice and duration of chemotherapy will be the next questions to be answered in the coming years in the field of HRPC, along with the role of new signal transduction inhibitors and other targeted therapies.

Original languageEnglish
Pages (from-to)53-62
Number of pages10
JournalExpert Review of Anticancer Therapy
Volume5
Issue number1
DOIs
Publication statusPublished - Feb 2005

Fingerprint

Prostatic Neoplasms
Hormones
Drug Therapy
Mitoxantrone
docetaxel
Prostate-Specific Antigen
Prednisone
Survival
Quality of Life
Estramustine
Vinca Alkaloids
Pain
Taxoids
Standard of Care
Microtubules
Cause of Death
Signal Transduction
Adrenal Cortex Hormones
Therapeutics
Serum

Keywords

  • Chemotherapy
  • Hormone-refractory prostate cancer
  • Microtubule inhibitor
  • Mitoxantrone
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. / Sava, Teodoro; Basso, Umberto; Porcaro, Antonio; Cetto, Gian Luigi.

In: Expert Review of Anticancer Therapy, Vol. 5, No. 1, 02.2005, p. 53-62.

Research output: Contribution to journalArticle

Sava, Teodoro ; Basso, Umberto ; Porcaro, Antonio ; Cetto, Gian Luigi. / New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. In: Expert Review of Anticancer Therapy. 2005 ; Vol. 5, No. 1. pp. 53-62.
@article{88abe52d72aa4fb9ada944dedf171bbd,
title = "New standards in the chemotherapy of metastatic hormone-refractory prostate cancer",
abstract = "Hormone-refractory prostate cancer (HRPC) is a major issue in Western countries and the second leading cause of cancer death in North American men. In the prostate-specific antigen era, most HRPCs are currently diagnosed in asymptomatic patients based on biochemical failure, with increasing demand for active treatment. Until recently, chemotherapy for HRPC patients was not considered a standard of care due to the absence of clear data evidencing an overall survival benefit. In fact, few Phase III studies conducted in the 1980s and early 1990s had documented a superiority over corticosteroids alone in terms of biochemical response (declines in serum prostate-specific antigen levels) and quality of life, but not survival. Due to their impact on pain control, mitoxantrone and prednisone were long considered the best regimen for symptomatic HRPC patients. In recent years, more chemotherapeutic agents have been tested, among which the microtubule inhibitors (vinca alkaloids and taxanes) have obtained the most promising results in Phase II trials and have entered Phase III testing. Two well-designed randomized trials have changed this scenario. Both compared docetaxel (with or without estramustine) against mitoxantrone and prednisone, and demonstrated a significant advantage not only in terms of response, pain control and quality of life, but also In terms of overall survival. Which patients need to be treated, the regimen of choice and duration of chemotherapy will be the next questions to be answered in the coming years in the field of HRPC, along with the role of new signal transduction inhibitors and other targeted therapies.",
keywords = "Chemotherapy, Hormone-refractory prostate cancer, Microtubule inhibitor, Mitoxantrone, Prostate-specific antigen",
author = "Teodoro Sava and Umberto Basso and Antonio Porcaro and Cetto, {Gian Luigi}",
year = "2005",
month = "2",
doi = "10.1586/14787210.5.1.53",
language = "English",
volume = "5",
pages = "53--62",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - New standards in the chemotherapy of metastatic hormone-refractory prostate cancer

AU - Sava, Teodoro

AU - Basso, Umberto

AU - Porcaro, Antonio

AU - Cetto, Gian Luigi

PY - 2005/2

Y1 - 2005/2

N2 - Hormone-refractory prostate cancer (HRPC) is a major issue in Western countries and the second leading cause of cancer death in North American men. In the prostate-specific antigen era, most HRPCs are currently diagnosed in asymptomatic patients based on biochemical failure, with increasing demand for active treatment. Until recently, chemotherapy for HRPC patients was not considered a standard of care due to the absence of clear data evidencing an overall survival benefit. In fact, few Phase III studies conducted in the 1980s and early 1990s had documented a superiority over corticosteroids alone in terms of biochemical response (declines in serum prostate-specific antigen levels) and quality of life, but not survival. Due to their impact on pain control, mitoxantrone and prednisone were long considered the best regimen for symptomatic HRPC patients. In recent years, more chemotherapeutic agents have been tested, among which the microtubule inhibitors (vinca alkaloids and taxanes) have obtained the most promising results in Phase II trials and have entered Phase III testing. Two well-designed randomized trials have changed this scenario. Both compared docetaxel (with or without estramustine) against mitoxantrone and prednisone, and demonstrated a significant advantage not only in terms of response, pain control and quality of life, but also In terms of overall survival. Which patients need to be treated, the regimen of choice and duration of chemotherapy will be the next questions to be answered in the coming years in the field of HRPC, along with the role of new signal transduction inhibitors and other targeted therapies.

AB - Hormone-refractory prostate cancer (HRPC) is a major issue in Western countries and the second leading cause of cancer death in North American men. In the prostate-specific antigen era, most HRPCs are currently diagnosed in asymptomatic patients based on biochemical failure, with increasing demand for active treatment. Until recently, chemotherapy for HRPC patients was not considered a standard of care due to the absence of clear data evidencing an overall survival benefit. In fact, few Phase III studies conducted in the 1980s and early 1990s had documented a superiority over corticosteroids alone in terms of biochemical response (declines in serum prostate-specific antigen levels) and quality of life, but not survival. Due to their impact on pain control, mitoxantrone and prednisone were long considered the best regimen for symptomatic HRPC patients. In recent years, more chemotherapeutic agents have been tested, among which the microtubule inhibitors (vinca alkaloids and taxanes) have obtained the most promising results in Phase II trials and have entered Phase III testing. Two well-designed randomized trials have changed this scenario. Both compared docetaxel (with or without estramustine) against mitoxantrone and prednisone, and demonstrated a significant advantage not only in terms of response, pain control and quality of life, but also In terms of overall survival. Which patients need to be treated, the regimen of choice and duration of chemotherapy will be the next questions to be answered in the coming years in the field of HRPC, along with the role of new signal transduction inhibitors and other targeted therapies.

KW - Chemotherapy

KW - Hormone-refractory prostate cancer

KW - Microtubule inhibitor

KW - Mitoxantrone

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=14244251251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14244251251&partnerID=8YFLogxK

U2 - 10.1586/14787210.5.1.53

DO - 10.1586/14787210.5.1.53

M3 - Article

C2 - 15757438

AN - SCOPUS:14244251251

VL - 5

SP - 53

EP - 62

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 1

ER -